S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
NASDAQ:CGEM

Cullinan Oncology (CGEM) Stock Price, News & Analysis

$17.04
-0.69 (-3.89%)
(As of 03/28/2024 ET)
Today's Range
$17.02
$17.79
50-Day Range
$11.51
$19.02
52-Week Range
$7.64
$19.68
Volume
394,192 shs
Average Volume
429,467 shs
Market Capitalization
$733.91 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$28.67

Cullinan Oncology MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
68.2% Upside
$28.67 Price Target
Short Interest
Healthy
3.56% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.43mentions of Cullinan Oncology in the last 14 days
Based on 2 Articles This Week
Insider Trading
Selling Shares
$1.44 M Sold Last Quarter
Proj. Earnings Growth
Growing
From ($3.55) to ($3.37) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.66 out of 5 stars

Medical Sector

485th out of 938 stocks

Biological Products, Except Diagnostic Industry

78th out of 152 stocks

CGEM stock logo

About Cullinan Oncology Stock (NASDAQ:CGEM)

Cullinan Oncology, Inc., a biopharmaceutical company, focuses on developing oncology therapies for cancer patients in the United States. The company's lead program comprises CLN-619, a monoclonal antibody that is in Phase I clinical trial for the treatment of solid tumors. Its development portfolio also includes CLN-049, a humanized bispecific antibody that is in Phase I clinical trial for the treatment of acute myeloid leukemia or myelodysplastic syndrome; CLN-418, a human bispecific immune activator that is in Phase 1 clinical trial for the treatment of multiple solid tumors; and Zipalertinib, a bioavailable small-molecule for treating patients with non-small cell lung cancer. In addition, the company's development products comprise CLN-617, a fusion protein for the treatment of solid tumors; and CLN-978, a T cell engaging antibody for the treatment relapsed/refractory B-cell non-Hodgkin lymphoma. It has license and collaboration agreement with Adimab, LLC to discover and/or optimize antibodies; Harbour BioMed US Inc. for the development, manufacturing, and commercialization of CLN-418; and co-development agreement with Taiho Pharmaceutical Co., Ltd to develop Zipalertinib. Cullinan Oncology, Inc. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.

CGEM Stock Price History

CGEM Stock News Headlines

Top Project Outperforms BTC in 2023…
According to a recently published report… One DeFi protocol boasted gains over 100% during one of the biggest crashes the crypto market has ever seen. And now, this crypto coin is set to soar in the parabolic bull run projected in 2024.
Cullinan Oncology: Q4 Earnings Insights
Top Project Outperforms BTC in 2023…
According to a recently published report… One DeFi protocol boasted gains over 100% during one of the biggest crashes the crypto market has ever seen. And now, this crypto coin is set to soar in the parabolic bull run projected in 2024.
Cullinan Oncology LLC (CGEM)
Recap: Cullinan Oncology Q3 Earnings
Cullinan Oncology Inc Ordinary Shares CGEM
See More Headlines
Receive CGEM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Cullinan Oncology and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/09/2021
Today
3/28/2024
Next Earnings (Estimated)
5/09/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
N/A
Current Symbol
NASDAQ:CGEM
Fax
N/A
Employees
85
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$28.67
High Stock Price Target
$34.00
Low Stock Price Target
$22.00
Potential Upside/Downside
+66.2%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
4 Analysts

Profitability

Net Income
$-153,160,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$18.94 million
Book Value
$10.61 per share

Miscellaneous

Free Float
39,268,000
Market Cap
$742.96 million
Optionable
Optionable
Beta
0.34
Ten Starter Stocks For Beginners to Buy Now Cover

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Key Executives

  • Mr. Nadim AhmedMr. Nadim Ahmed (Age 56)
    President, CEO & Director
    Comp: $1.16M
  • Mr. Jeffrey TrigilioMr. Jeffrey Trigilio (Age 40)
    CFO & Treasurer
    Comp: $922.61k
  • Dr. Jeffrey Jones M.B.A. (Age 53)
    M.D., M.P.H., Chief Medical Officer
    Comp: $780.32k
  • Dr. Patrick A. Baeuerle Ph.D. (Age 66)
    Co-Founder, Chief Scientific Advisor & Chairman of Scientific Advisory Board
    Comp: $763.73k
  • Dr. Jennifer Michaelson Ph.D. (Age 57)
    Chief Scientific Officer
  • Ms. Jacquelyn L. Sumer J.D. (Age 46)
    Chief Legal Officer, Chief Compliance Officer & Corporate Secretary
  • Ms. Rose Weldon
    Senior Vice President of Communications
  • Mr. Steve Andre
    Chief Human Resources Officer
  • Dr. Corinne Savill Ph.D. (Age 65)
    Chief Business Officer
  • Mr. Kevin A. Johnston
    Chief Technical Operations Officer

CGEM Stock Analysis - Frequently Asked Questions

Should I buy or sell Cullinan Oncology stock right now?

4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Cullinan Oncology in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" CGEM shares.
View CGEM analyst ratings
or view top-rated stocks.

What is Cullinan Oncology's stock price target for 2024?

4 brokerages have issued 12-month price objectives for Cullinan Oncology's stock. Their CGEM share price targets range from $22.00 to $34.00. On average, they expect the company's stock price to reach $28.67 in the next twelve months. This suggests a possible upside of 68.2% from the stock's current price.
View analysts price targets for CGEM
or view top-rated stocks among Wall Street analysts.

How have CGEM shares performed in 2024?

Cullinan Oncology's stock was trading at $10.19 at the beginning of 2024. Since then, CGEM shares have increased by 67.2% and is now trading at $17.04.
View the best growth stocks for 2024 here
.

Are investors shorting Cullinan Oncology?

Cullinan Oncology saw a increase in short interest during the month of March. As of March 15th, there was short interest totaling 935,400 shares, an increase of 34.8% from the February 29th total of 694,100 shares. Based on an average daily volume of 402,300 shares, the days-to-cover ratio is currently 2.3 days. Approximately 3.6% of the shares of the company are short sold.
View Cullinan Oncology's Short Interest
.

When is Cullinan Oncology's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024.
View our CGEM earnings forecast
.

How were Cullinan Oncology's earnings last quarter?

Cullinan Oncology, Inc. (NASDAQ:CGEM) released its quarterly earnings data on Tuesday, November, 9th. The company reported ($0.40) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.42) by $0.02.

When did Cullinan Oncology IPO?

Cullinan Oncology (CGEM) raised $149 million in an IPO on Friday, January 8th 2021. The company issued 8,300,000 shares at $17.00-$19.00 per share. Morgan Stanley, SVB Leerink and Evercore ISI acted as the underwriters for the IPO and H.C. Wainwright & Co., LLC was co-manager.

Who are Cullinan Oncology's major shareholders?

Cullinan Oncology's stock is owned by many different retail and institutional investors. Top institutional investors include Blue Owl Capital Holdings LP (7.99%), Franklin Resources Inc. (7.67%), Vanguard Group Inc. (4.14%), Vanguard Group Inc. (4.14%), Braidwell LP (2.90%) and American International Group Inc. (2.89%). Insiders that own company stock include Ansbert Gadicke, Bioscience I 2017 Ltd F2, Bvf Partners L P/Il, Corrine Savill, Jeffrey Alan Jones, Jeffrey Trigilio, Jennifer Michaelson, Leigh Zawel, Nadim Ahmed, Oncology Impact Fund LP Ubs and Vision Scs F2.
View institutional ownership trends
.

How do I buy shares of Cullinan Oncology?

Shares of CGEM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:CGEM) was last updated on 3/29/2024 by MarketBeat.com Staff

From Our Partners